JW Pharmaceutical Corporation

JW PHARMACEUTICAL CORP Pfd Shs Non-Voting's next confirmed earnings release is scheduled for November 18, 2026.

As of June 30, 2026, JW PHARMACEUTICAL CORP Pfd Shs Non-Voting maintains a current ratio of 1.56, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, JW PHARMACEUTICAL CORP Pfd Shs Non-Voting posted a return on equity (ROE) of 27.93, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 23.90 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 16.21, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 22.62, useful for judging operating efficiency across full business cycles. The company generates approximately 742.02M in revenue per employee across its workforce of 1,106.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.74 indicates how many times JW PHARMACEUTICAL CORP Pfd Shs Non-Voting sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, JW PHARMACEUTICAL CORP Pfd Shs Non-Voting recorded 14.02B in income tax expense. That works out to an effective tax rate of 12.16, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 115.30B, leaving 101.28B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, JW PHARMACEUTICAL CORP Pfd Shs Non-Voting's stock has declined approximately 22.26% over the past 52 weeks. The 50-day moving average sits at 22,248.00, while the 200-day moving average is 24,570.40.

These figures cover the twelve months ended June 30, 2026. EBITDA reached 133.89B, while operating income came in at 114.40B.

As of June 30, 2026, JW PHARMACEUTICAL CORP Pfd Shs Non-Voting holds 102.08B in cash and equivalents against 71.75B in total debt, resulting in a net debt position of 5.96B. Total book value stands at 405.90B, with working capital of 123.86B providing operational flexibility.

JW PHARMACEUTICAL CORP Pfd Shs Non-Voting produced 134.48B in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, JW PHARMACEUTICAL CORP Pfd Shs Non-Voting posted a gross margin of 47.29, reflecting its pricing power and cost economics. The operating margin of 13.94 and net profit margin of 12.34 provide insight into operational efficiency.

JW PHARMACEUTICAL CORP Pfd Shs Non-Voting's most recent stock split took place on December 27, 2023 with a 50:51 split ratio.